Navigation Links
Takeda Completes its Russian Pharmaceutical Manufacturing Facility
Date:9/11/2012

ZURICH, September 11, 2012 /PRNewswire/ --

 

  • State-of-the-art facility in Yaroslavl demonstrates Takeda's long-term commitment to the Russian market
  • Plant expected to be fully operational in 2014, supplying high quality tablet and sterile liquid products for the local market
  • €75 million investment

Takeda Pharmaceutical International GmbH ("Takeda") today announced the completion of construction at its pharmaceutical manufacturing facility in Yaroslavl, Russia.  The Company has invested approximately €75 million in the 24,000m2 production plant, which is expected to be fully operational by 2014.

Takeda was one of the first major international companies to have invested in high quality pharmaceutical manufacturing in Russia, demonstrating its long-term commitment to the market.  Based on sales Takeda is the 7th largest pharmaceutical company in Russia. According to IMS Health, Russian pharmaceutical sales totaled $14.7 billion* in 2011, making it the 11th largest pharmaceutical market in the world. Market sales in Russia/CIS are expected to grow at a compound annual rate of 11%* between 2012 and 2016.  Takeda plans to outgrow the market with an annual growth rate of 15% over the same period.

The Yaroslavl facility will enable Takeda to meet demand in Russia, initially Cardiomagnyl, Actovegin and Calcium tablets.  It will lead to creation of initially around 200 positions for highly qualified managers and technical staff.

The plant, which is approximately 280 kilometers from Moscow, was constructed on time and on budget to local and international GMP standards and adheres to the latest safety and environmental standards.  It will have the initial capacity to manufacture 90 million sterile ampoules and more than two billion tablets per year.  Liquid sterile pr
'/>"/>

SOURCE Takeda
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
2. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
3. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
4. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
5. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
6. NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobiotic™ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels
7. CryoLife Completes Acquisition of Hemosphere
8. Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals
9. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
10. Jazz Pharmaceuticals Completes EUSA Pharma Acquisition
11. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 26, 2014 Investor-Edge has initiated ... VVUS ), Horizon Pharma PLC (NASDAQ: HZNP ), ... (NYSE: JNJ ), and Theravance Inc. (NASDAQ: ... be accessed at: http://investor-edge.com/register . On Tuesday, ... 0.07%, the Dow Jones Industrial Average edged 0.02% lower, to ...
(Date:11/26/2014)... A hernia is condition in which ... the wall of a weak muscle area. Obesity, poor nutrition, ... of the causes of hernias. There are several types of ... inguinal hernia is when part of the abdominal tissue/organ protrudes ... the area of the umbilicus. A hiatal hernia is when ...
(Date:11/26/2014)... Calif. , Nov. 26, 2014  Aridis ... to produce novel therapies for infectious diseases, announced ... M.D., an internationally recognized key opinion leader in ... Company,s scientific advisory board. Founder and ... stated, "We believe Dr. Opal,s extensive experience investigating ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 2Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 3Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 4Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3
... a leading developer of innovative catheters and stents for ... closing of a $17M Round D financing.  The financing ... based EDB Investments (,EDBI,) with strong support from current ... are delighted to have Bio*One join our group of ...
... Arable Corporation ( www.arablecorp.com ) has announced the launch ... the clinical trial industry.  Whereas traditional CTMS systems have ... CTMS and EDC capabilities without the traditionally high start-up ... or CROs to manage the planning and implementation of ...
Cached Medicine Technology:TriReme Medical Announces $17 Million Series D Financing 2Arable Corporation Announces New Technology for Clinical Trial Industry 2
(Date:11/27/2014)... November 27, 2014 Now that Thanksgiving ... has officially launched, Emassagechair.com has announced its ... Discount Event. , Negotiating on behalf of their ... massage chair brands, Emassagechair.com has generated significant buzz in ... and biggest discounts yet. , Shoppers are excited for ...
(Date:11/27/2014)... 2014 VogueQueen.com is making every effort ... across the world. As the premier online supplier of ... proud to release a huge selection of sexy prom ... it is also providing many beautiful styles in its ... at discounted prices. , “VogueQueen.com hopes to provide ...
(Date:11/27/2014)... Viejo, California (PRWEB) November 27, 2014 Developers ... announced a new plugin entitled ProPip, taking FCPX to the ... in picture effect with a few clicks of a mouse,” ... a time saver that our users will appreciate.” , With ... full customization leaving the possibilities truly endless. ProPip is great ...
(Date:11/27/2014)... 27, 2014 HealthPostures, a ... equipment , has announced that it has entered ... Environments. The partnership will put HealthPostures' products into ... , In addition to having its products sold ... promotes HealthPostures' products with the business decision makers ...
(Date:11/27/2014)... November 27, 2014 At The Little ... So it came as no surprise when a recent ... child’s academic success. The Journal of Pediatrics ... and motor tasks during the school years may be ... academic development.” The study monitored two groups of children; ...
Breaking Medicine News(10 mins):Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2
... Care at the 15th SPSSCS Annual Meeting , ... New York, NY ... Specialists (SPSSCS) celebrates its 15th Annual Meeting - Play the Winning Hand: ... Vegas, NV. The meeting offers educational seminars for nurses, aestheticians ...
... Aeroportuario del Sureste, S.A.B. de C.V. (NYSE: ASR ... in Mexico and operator of Cancun Airport and eight others ... 26, 2009 the Mexican Secretary of Health confirmed the presence ... 28, 2009 the World Health Organization (the "WHO") acknowledged the ...
... Executive Chairman & CEO Douglas MacLellan offers expert insight ... April 29 AMDL Inc. ... major operations in China, announced today its Executive Chairman ... featured in The Wall Street Transcript - ...
... 23 June 2009, the Prostate Cancer Translational Research ... the Beurs van Berlage in Amsterdam (NL). Translational ... or population studies into clinical applications to reduce ... Association of Urology (EAU) provides an excellent forum ...
... Sales & Marketing Data In One Screen To ... Custom Metrics EWING, N.J., April 29 Archi-Tech ... reporting solutions, today announced the availability of managed ... portal for pharmaceutical sales reporting. Using InView, managed ...
... New analyses of data from the 16-Year ... by Bayer HealthCare Pharmaceuticals, were presented at the ... The study results showed that early and ... multiple sclerosis (MS) were more likely to avoid ...
Cached Medicine News:Health News:Play the Winning Hand - Watching Your Fortunes Grow in Skin Care 2Health News:Play the Winning Hand - Watching Your Fortunes Grow in Skin Care 3Health News:Chinese Pharma Market Continues to Grow at a 5-7% Rate in 2009; AMDL Remains on Track to Meet FY09 Financial Targets 2Health News:Chinese Pharma Market Continues to Grow at a 5-7% Rate in 2009; AMDL Remains on Track to Meet FY09 Financial Targets 3Health News:EAU Research Foundation organizes meeting in Amsterdam highlighting translational research results 2Health News:Archi-Tech InView Now Supports Managed Care Data, Offering an Interactive Dashboard for On-Demand Sales Planning and Reporting 2Health News:New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes 2Health News:New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes 3Health News:New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes 4